Policy to review limited use of therapeutic drug "chloroquine" for patients French Government May 24, 10:08

Following the announcement of research results that the effect of the new drug "chloroquine" such as malaria, which has been pointed out to be effective for the treatment of the new coronavirus, has been limited to patients The policy to revise the regulations that allow specific use is shown.

It has been pointed out that the therapeutic drug "chloroquine" such as malaria and its kind "hydroxychloroquine" may be effective for the treatment of the new coronavirus, but research groups in the United States and Switzerland on the 22nd reported about 96,000. The results of the study were published, saying that "no effect was observed" based on an analysis of human data, and abnormal heart rate was observed in some of the treated patients.

In response, France's Minister of Health, Belin, wrote to Twitter on Wednesday, "I asked a panel of experts to analyze the research results and review the rules of use within 48 hours."

France is currently allowing limited use of "hydroxychloroquine" in clinical trials or in severely ill patients, but it is likely that the regulations will be revised in response to research results.

Regarding "Hydroxychloroquine", it was revealed that President Trump of the United States was taking it himself, but WHO = World Health Organization and others called attention to use as it is unknown whether it is effective or not, Since the beginning of this month, a series of negative research results have been published.